Drug therapy of arterial hypertension: assessment of the senior students’ basic knowledge. Final results of the PHYSTARH project

Introduction. Arterial hypertension (AH) is the main correctable cause of the development of cardiovascular diseases, leading to dysfunction of many organs, including the heart, blood vessels and kidneys. Lack of adequate control of systolic and/or diastolic blood pressure can lead to life-threatening conditions and death.

The aim of study is to analyze the senior medical students’ knowledge from different regions of Russia in the basic issues of hypertension therapy.

Materials and methods. The article presents the results of the first stage of the PHYSTARH multicenter study (the full name of the project is Physicians’ and undergraduates’ knowledge in arterial hypertension treatment): an anonymous survey among 285 senior medical students from 4 cities of Russia. In this article, the authors analyzed the questions of the second part of the questionnaire.

Results. The average level of correct answers on the questionnaire was 57.7%. The minimum level of correct answers was obtained in questions about the effectiveness of combined therapy, as well as the choice of absolute contraindications to the use of antihypertensive drugs. The maximum level of correct answers was registered in the question about determining the drug to its pharmacological group.

Conclusion. The obtained results testify to the insufficiently level of students’ knowledge in the basic issues of arterial hypertension therapy.

1. Global Health Estimates: Life expectancy and leading causes of death and disability // THE GLOBAL HEALTH OBSERVATORY URL: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates (дата обращения: 18.05.2021).

2. NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. The Lancet. 2021; 398(10304):957-980. https://doi.org/10.1016/S0140-6736(21)01330-1

3. Bontsevich R, Chernykh A, Leonova A, et al. Physicians’ and undergraduates’ knowledge of drugs contraindicated for arterial hypertension treatment. Eur J Clin Pharmacol. 2019;75(Suppl. 1):S28(EACPT1241). The Abstracts: 14th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT). 29 June — 2 July 2019, Stockholm, Sweden. https://doi.org/10.1007/s00228-019-02685-2

4. Bontsevich RA, Vovk YaR, Gavrilova AA, et al. Physicians’ and senior medical students’ knowledge of drugs contraindicated for arterial hypertension treatment according to the PHYSTARH study. Sys Rev Pharm. 2020;11(6):26-30. https://doi.org/10.31838/srp.2020.6.06

5. Bontsevich R.A., Vovk Y.R., Gavrilova A.A., Kirichenko A.A., Krotkova I.F., Kosmacheva E.D., Kompaniets O.G., Prozorova G.G., Nevzorova V.A., Martynenko I.M., Ketova G.G., Barysheva V.O., Maksimov M.L., Osipova O.A. Drug therapy of arterial hypertension: assessment of the physicians’ basic knowledge. Final results of the PHYSTARH project. Systemic Hypertension. 2021;18(2):80-87. (in Russ.) https://doi.org/10.26442/2075082X.2021.2.200884

6. Batishcheva G.A., Goncharova N.I., Elizarova I.O., Ketova G.G., Barysheva V.O., Bikkinina G.M., Myronenko O.V. Knowledge of senior students in the definition, classification, and approaches to the treatment of arterial hypertension. Final results of the PHYSTARH project. Systemic Hypertension. 2021;18(4):169-174. (in Russ.)] https://doi.org/10.26442/2075082X.2021.4.200897

7. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reduction blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290-300. https://doi.org/10.1016/j.amjmed.2008.09.038

8. Chazova IE, Zhernakova YuV on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6-31 (in Russ.)]. https://doi.org/10.26442/2075082X.2019.1.190179

9. Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786 (in Russ.)]. https://doi.org/10.15829/1560-4071-2020-3-3786

10. Mancia G, Fagard R, Narkiewicz K, et al.; Task Force Members. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281-357. https://doi.org/10.1097/01.hjh.0000431740.32696.cc

11. Bontsevich RA, Severinova OV, Chukhareva NA, et al. The successful clinical case of a severe arterial hypertension management during preconception and pregnancy. Indo Am J P Sci. 2018;5(10):10396-400. https://doi.org/10.5281/zenodo.1467395

12. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-60. https://doi.org/10.1016/S0140-6736(09)60503-1

13. Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010;56(12):956-65. https://doi.org/10.1016/j.jacc.2010.02.068

14. Kharina VI, Berezhnova TA. Evaluation of the effectiveness of pharmacotherapy for brain and heart diseases by monitoring the effects of drugs. Research Results in Pharmacology. 2020;6(2):43-55. https://doi.org/10.3897/rrpharmacology.6.52300

15. Pribylov SA, Shabanov EA, Aliullin RV, et al. Endothelioprotective and hemodynamic effects of sartans in conjunction with arterial hypertension, coronary heart disease and chronic obstructive pulmonary disease. Actual Problems of Medicine. 2011;16(111). Available at: https://cyberleninka.ru/article/n/endotelioprotektornye-i-gemodinamicheskie-effekty-sartanov-pri-sochetanii-arterialnoy-gipertenziiishemicheskoy-bolezni-serdtsa-i. Accessed: 31.03.2021 (in Russ.)

16. Williams B, MacDonald TM, Morant S, et al.; British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059-68. https://doi.org/10.1016/s0140-6736(15)00257-3

17. Liu L, Xu B, Ju Y. Addition of spironolactone in patients with resistant hypertension: a meta-analysis of randomized controlled trials. Clin Exp Hypertens. 2017;39(3):257-63. https://doi.org/10.1080/10641963.2016.1246564

18. Wang C, Xiong B, Huang J. Efficacy and Safety of Spironolactone in Patients with Resistant Hypertension: A Meta-analysis of Randomised Controlled Trials. Heart Lung Circ. 2016;25(10):1021-30. https://doi.org/10.1016/j.hlc.2016.02.016